作者
David Humberto Marmolejo, Mark Yu Zheng Wong, Svetlana Bajalica-Lagercrantz, Marc Tischkowitz, Judith Balmaña, Attila Balázs Patócs, Pierre Chappuis, Chrystelle Colas, Maurizio Genuardi, Maria Haanpää, Hildegunn Hoberg Vetti, Nicoline Hoogerbrugge, Arvids Irmejs, Tiina Kahre, Barbara Klink, Mateja Krajc, Tamara Hussong Milagre, Robin de Putter, Verena Steinke-Lange, Karin Wadt, Katharina Wimmer
发表日期
2021/12/1
来源
European Journal of Medical Genetics
卷号
64
期号
12
页码范围
104350
出版商
Elsevier Masson
简介
Hereditary breast and ovarian cancer (HBOC) is a syndrome defined by an increased risk of developing breast and/or ovarian cancer most commonly due to germline disease-causing variants in the BRCA1 and BRCA2 genes, but also other causative genes such as PALB2, ATM and CHEK2. As genetic testing becomes more prevalent and new clinical data emerge, updates of national guidelines are required to incorporate these advances in our knowledge. The aim of this work is to review the guidelines for HBOC genetic testing and clinical surveillance across European countries, mostly affiliated to the European Reference Network (ERN) for Genetic Tumor Risk Syndroms (GENTURIS). Young onset breast cancer (BC), triple negative phenotype, or bilateral BC are considered as criteria for genetic testing in all, with differences in age limits. Testing of invasive epithelial non-mucinous ovarian cancer is also …
引用总数
学术搜索中的文章
DH Marmolejo, MYZ Wong, S Bajalica-Lagercrantz… - European Journal of Medical Genetics, 2021